Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)
Hong Kong · Delayed Price · Currency is HKD 3.650
+0.020 (0.55%)
Aug 27, 2026, 2:47 PM HKT
HKG:2563 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 50.5 | 28.65 | 71.87 | 66.64 | 32.82 | 71.06 |
Other Revenue | 4.72 | 4.72 | - | - | - | - |
| 55.21 | 33.36 | 71.87 | 66.64 | 32.82 | 71.06 | |
Revenue Growth | 3.14% | -53.57% | 7.85% | 103.03% | -53.82% | - |
Cost of Revenue | 4.14 | 2.62 | 9.81 | 19.81 | 8.94 | 4.17 |
Gross Profit | 51.07 | 30.74 | 62.05 | 46.83 | 23.88 | 66.89 |
Selling, General & Admin | 65.98 | 65.61 | 114.2 | 139.3 | 149.41 | 267.37 |
Research & Development | 60.71 | 82.99 | 116.29 | 126.54 | 82.74 | 91.97 |
Other Operating Expenses | 1.49 | 1.09 | 1.04 | -1.25 | -15.25 | 0.96 |
Operating Expenses | 149.27 | 170.34 | 231.82 | 263.3 | 218.11 | 360.69 |
Operating Income | -98.19 | -139.6 | -169.77 | -216.47 | -194.23 | -293.79 |
Interest Expense | -0.05 | -0.05 | -0.06 | -0.06 | -0.07 | -0.07 |
Interest & Investment Income | 15.66 | 16.34 | 18.35 | 13.14 | 3.34 | 14.11 |
Currency Exchange Gain (Loss) | -10.18 | -10.18 | 5.54 | 4.65 | 19.6 | -4.9 |
Other Non Operating Income (Expenses) | -13.36 | -0.05 | -0.05 | - | - | -0.03 |
EBT Excluding Unusual Items | -106.13 | -133.53 | -145.99 | -198.74 | -171.36 | -284.68 |
Gain (Loss) on Sale of Investments | -0 | -0.05 | 0.49 | 9.1 | 10.85 | 8.46 |
Asset Writedown | -2.36 | -2.36 | -0.29 | - | - | - |
Other Unusual Items | 4.51 | 4.51 | 2.01 | - | - | -1.92 |
Pretax Income | -103.99 | -131.44 | -143.78 | -189.64 | -160.51 | -278.14 |
Net Income | -103.99 | -131.44 | -143.78 | -189.64 | -160.51 | -278.14 |
Net Income to Common | -103.99 | -131.44 | -143.78 | -189.64 | -160.51 | -278.14 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | 365 | 351 | 350 | 350 | 350 |
Shares Outstanding (Diluted) | - | 365 | 351 | 350 | 350 | 350 |
Shares Change | - | 4.11% | 0.19% | - | - | - |
EPS (Basic) | - | -0.36 | -0.41 | -0.54 | -0.46 | -0.79 |
EPS (Diluted) | - | -0.36 | -0.41 | -0.54 | -0.46 | -0.79 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -156.94 | -153.39 | -178.62 | -111.3 | -89.83 |
Free Cash Flow Per Share | - | -0.43 | -0.44 | -0.51 | -0.32 | -0.26 |
Gross Margin | 92.50% | 92.13% | 86.35% | 70.27% | 72.76% | 94.13% |
Operating Margin | -177.84% | -418.41% | -236.23% | -324.87% | -591.81% | -413.42% |
Profit Margin | -188.34% | -393.94% | -200.06% | -284.60% | -489.06% | -391.40% |
Free Cash Flow Margin | - | -470.38% | -213.45% | -268.05% | -339.12% | -126.41% |
EBITDA | -88.07 | -130.12 | -161.08 | -207.3 | -185.14 | -286.11 |
EBITDA Margin | -159.52% | - | -224.14% | - | - | - |
D&A For EBITDA | 10.12 | 9.48 | 8.68 | 9.17 | 9.1 | 7.69 |
EBIT | -98.19 | -139.6 | -169.77 | -216.47 | -194.23 | -293.79 |
EBIT Margin | -177.84% | - | -236.23% | - | - | - |